Clinical Observation about Entecavir in Treating Chronic Hepatitis B at the Initial Stage.

Objective To evaluate the 24-week therapeutic effects and safety of anti-virus therapy of entecavir in patients with chronic hepatitis B(CHB). Method 70 CHB cases were divided into the treatment group and the control group.Patients were given with entecarvir(0.5mg po qd) in the treatment group,while the others were given interferon α-2b(300MU im qod) in the control group.Result In the treatment group,the level of serum HBV DNA was obviously decreased than that before treatment at the 8th week.At the 12th week the ratio of negative transformation of HBV DNA and HBeAg were separately 26.7% and 33.3%,which was superior to the control group;the ratio of recovery of liver function was 90%.There was higher ratio of early response of anti-virus therapy.At the 24th week,the ratio of negative transformation of HBV DNA and HBeAg were separately 56.7% and 73.3%,which was superior to the control group and before treatment;the ratio of recovery of liver function was 100%.There was no serious adverse event related with entecavir. Conclusion Entecavir can inhibit the replication of hepatitis B virus and have good safety and tolerance.